Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $84,893.22 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,879 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $45.18, for a total value of $84,893.22. Following the sale, the director now directly owns 352,996 shares in the company, valued at $15,948,359.28. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Pro-Dex Price Performance

Shares of PDEX opened at $44.35 on Friday. The company has a 50 day moving average of $48.26 and a two-hundred day moving average of $32.85. The company has a quick ratio of 1.94, a current ratio of 3.41 and a debt-to-equity ratio of 0.36. Pro-Dex, Inc. has a twelve month low of $16.18 and a twelve month high of $59.60. The company has a market cap of $144.58 million, a price-to-earnings ratio of 28.80 and a beta of 0.56.

Institutional Trading of Pro-Dex

Several hedge funds and other institutional investors have recently made changes to their positions in PDEX. JPMorgan Chase & Co. grew its stake in Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares in the last quarter. FMR LLC grew its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the last quarter. Bard Associates Inc. increased its stake in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 2,031 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares during the last quarter. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Analysts Set New Price Targets

PDEX has been the subject of a number of analyst reports. Ascendiant Capital Markets upped their price objective on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.